Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150441 | 0.86 | ALDH1A1 (0.37) | SMN1; SMN2ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL5768524 | 0.84 | KMT2A (0.48) | SMN1; SMN2NPC1RAB9AALDH1A1HTT | |
| SCHEMBL15995601 | 0.83 | ALDH1A1 (0.36) | SMN1; SMN2ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL169064 | 0.80 | — | — | |
| SCHEMBL5768783 | 0.79 | KMT2A (0.47) | SMN1; SMN2ADORA2AADORA1NPC1RAB9A | |
| SCHEMBL22726168 | 0.79 | PARP1 (0.39) | SMN1; SMN2CYP1A2NPC1RAB9ACNR1 | |
| SCHEMBL466479 | 0.78 | — | — | |
| SCHEMBL21176491 | 0.77 | GABRR1 (0.35) | SMN1; SMN2CYP1A2ALDH1A1ALPL | |
| SCHEMBL27837519 | 0.77 | ALDH1A1 (0.47) | SMN1; SMN2ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL7527727 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-27 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-11008358-B2 | Synthesis of desosamines | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-05-18 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-05 | — | — | US | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180066008-A1 | MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-03-08 | — | — | US | disclosed |
| US-8283358-B2 | N-sulfonamido polycyclic pyrazolyl compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| CN-1913898-A | Substituted piperazines | CHEMOCENTRYX INC (US) | 2007-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180066008-A1 | MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF | FUT6, MGAM, B3GNT2 | SMN1; SMN2 3358/4885ADORA3 3308/4885ADORA2A 2672/4885 |
| US-11008358-B2 | Synthesis of desosamines | NANS, GALE, FUT6 | SMN1; SMN2 4172/4885ADORA3 2496/4885ADORA2A 2407/4885 |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | SMN1; SMN2 3387/4885ADORA3 36/4885ADORA2A 170/4885 |
| US-20240208985-A2 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | AR, SHBG, NR5A1 | SMN1; SMN2 4522/4885ADORA3 363/4885ADORA2A 247/4885 |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | SMN1; SMN2 4172/4885ADORA3 2496/4885ADORA2A 2407/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | SMN1; SMN2 285/4885ADORA3 325/4885ADORA2A 269/4885 |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | PSEN1, PSEN2, SULT1E1 | SMN1; SMN2 101/4885ADORA3 123/4885ADORA2A 720/4885 |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | SMN1; SMN2 4172/4885ADORA3 2496/4885ADORA2A 2407/4885 |
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | SMN1; SMN2 4064/4885ADORA3 506/4885ADORA2A 1801/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | SMN1; SMN2 3143/4885ADORA3 3876/4885ADORA2A 3401/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | SMN1; SMN2 3489/4885ADORA3 3906/4885ADORA2A 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.